N-Acetyl Selank – 10MG

Scientific Overview of N-Acetyl Selank

N-Acetyl Selank is an acetylated derivative of the synthetic peptide Selank. Selank itself is modeled after tuftsin, a naturally occurring immunomodulatory tetrapeptide. The modification of Selank through acetylation appears to provide greater molecular stability, which may enhance its persistence under laboratory conditions.

Early investigations suggest that N-Acetyl Selank may share many of the observed functions of Selank, while also presenting potential differences due to the acetyl group. Research indicates that Selank and its derivatives may influence neurotransmission, neuromodulation, and aspects of brain signaling, including plasticity. These proposed roles have led to a growing body of experimental work aimed at understanding how N-Acetyl Selank interacts with central nervous system pathways and how it compares to Selank in laboratory settings.

Alternative Names: Ac-Selank, Acetylated Selank

N-Acetyl Selank Studies and Research Data

Explorations in Learning and Memory

Experimental work in rodent models suggests that Selank and its acetylated form may influence serotonin metabolism in the brain. Serotonin pathways are frequently implicated in learning and memory processes, and observations point toward a possible enhancement of memory consolidation under peptide exposure. Comparative studies propose that introducing Selank in controlled settings may facilitate improved storage and retrieval of memory traces relative to placebo groups.

N-Acetyl Selank Investigations in Stress and Anxiety Models

Several studies have explored Selank’s potential in relation to anxiety-associated states. Research in laboratory animals has suggested that the peptide may elevate levels of neurotransmitters involved in calming pathways, including serotonin. Additional investigations, conducted in controlled models of generalized anxiety disorder and related conditions, compared Selank with standard control compounds. Findings propose that while both the peptide and the control compounds influenced markers of anxiety, Selank also appeared to show indications of broader activity such as antiasthenic and psychostimulant-like outcomes. Mechanistically, Selank has been observed to inhibit enkephalin-degrading enzymes, which may underlie its reported anxiolytic properties in experimental contexts.

Neuroplasticity and BDNF Regulation

Research into brain plasticity has highlighted a potential link between Selank administration and the regulation of brain-derived neurotrophic factor (BDNF). In rodent models, Selank presentation was associated with increased BDNF expression in the hippocampus, a brain region central to memory and adaptation. BDNF is a protein known to support neuronal growth, synaptic remodeling, and the establishment of new neural connections. Additional laboratory work suggests that enhancing BDNF signaling may contribute to long-term adaptations in the nervous system, making this an important focus for future Selank and N-Acetyl Selank research.

Conclusion

N-Acetyl Selank represents an acetylated derivative of the synthetic peptide Selank, designed to enhance chemical stability. Across studies, research suggests possible roles in memory processes, anxiety-related signaling, and the regulation of neuroplasticity. Evidence from animal and laboratory models points to interactions with serotonin metabolism, enkephalin regulation, and BDNF expression. While the findings remain preliminary and exploratory, they indicate that N-Acetyl Selank may serve as a relevant model compound in ongoing peptide and neuroscience research.

References

1. Semenova TP, Kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Experimental optimization of learning and memory processes by selank]. Eksp Klin Farmakol. 2010 Aug;73(8):2-5. Russian. PMID: 20919548.
2. Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001 Apr;131(4):315-7. doi: 10.1023/a:1017979514274. PMID: 11550013.
3. Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. Russian. PMID: 25176261.
4. Deister C, Schmidt CE. Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng. 2006 Jun;3(2):172-9. doi: 10.1088/1741-2560/3/2/011. Epub 2006 May 16. PMID: 16705273.
5. Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. Russian. PMID: 18454096.
6. Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008 Jul-Aug;421:241-3. doi: 10.1134/s0012496608040066. PMID: 18841804.
7. Lu B, Figurov A. Role of neurotrophins in synapse development and plasticity. Rev Neurosci. 1997 Jan-Mar;8(1):1-12. doi: 10.1515/revneuro.1997.8.1.1. PMID: 9402641.
8. Semenova TP, kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. Eksp Klin Farmakol. 2009 Jul-Aug;72(4):6-8. Russian. PMID: 19803361.
9. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci. 1998 Jul;11(4):234-45. doi: 10.1006/mcne.1998.0684. PMID: 9675054.
10. Medvedev VE, Tereshchenko ON, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Myasoedov NF. [Optimization of the treatment of anxiety disorders with selank]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. Russian. doi: 10.17116/jnevro20151156133-40. PMID: 26356395.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.